Neuronasal
Phase 1NN has developed a novel nose to brain route for n-acetylcysteine (NAC) which is patent protected and has been shown to deliver drug to the targeted brain regions in a human pilot trial.
Founded
2018
Focus
Drug Delivery
About
NN has developed a novel nose to brain route for n-acetylcysteine (NAC) which is patent protected and has been shown to deliver drug to the targeted brain regions in a human pilot trial.
Company Info
TypePrivate
Founded2018
LocationSan Diego, United States
StagePhase 1
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile